• CLINIMARK: GOOD BIOMARKER PRACTICE TO INCREASE THE NUMBER OF CLINICALLY VALIDATED BIOMARKERS.

    CLINIMARK: GOOD BIOMARKER PRACTICE TO INCREASE THE NUMBER OF CLINICALLY VALIDATED BIOMARKERS.

  • THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.

    THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.

  • IMPROVING THE PIPELINE FROM BIOMARKER RESEARCH TO MARKET

    IMPROVING THE PIPELINE FROM BIOMARKER RESEARCH TO MARKET

  • THE CLINIMARK NETWORK WILL FOCUS ON THE ANALYTICAL AND CLINICAL  VALIDATION OF BIOMARKERS TO IMPROVE THE TRANSITION OF BIOMARKERS FROM THE RESEARCH TO THE MARKET PHASE

    THE CLINIMARK NETWORK WILL FOCUS ON THE ANALYTICAL AND CLINICAL VALIDATION OF BIOMARKERS TO IMPROVE THE TRANSITION OF BIOMARKERS FROM THE RESEARCH TO THE MARKET PHASE

COST Association COST Action CA16113

THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.
Thousands of circulating proteins have been shown to be hallmarks of emerging disease, response to treatment, or a patients’ prognosis. The identification of these small molecule biomarkers holds great promise for significant improvement of personalized medicine based on simple blood tests.
For instance, diagnosis and prognosis with biomarkers (e.g. carcinoembryonic antigen (CEA)) has significantly improved patient survival and decreased healthcare costs in colorectal cancer patients. Unfortunately, despite significant investments to increase the number of biomarker studies, only ~150 out of thousands of identified biomarkers have currently been implemented in clinical practice.

Action details

Memorandum of Understanding

112/16

CSO Approval date

24/10/2016

Start of Action

14/03/2017

End of Action

13/03/2021

Research Outputs

Updates on the research outputs of CliniMARK are provided on this page.

International peer-reviewed journal articles

CliniMARK working papers

Related publications

Management Committee & Working Group Leaders

News & Events

CliniMark Cost Action Meeting
September 21st - 22nd 2019, Athens - Greece

The CliniMARK Athens meeting presented unique opportunities for international collaborationson the disseminationof biomarker practice. During the meeting,participants agreed on a specific plan for writing several publications. Amongst them wasa review on analytical techniques forprotein biomarker validation focusing on multiplex detection of soluble biomarkers with clinicalapplications, which should be submitted by the end of 2019.

Handbook of Biomarkers and Precision Medicine.

"Handbook of Biomarkers and Precision Medicine" provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments.

Edited by Carini C, Fidock MD and van Gool AJ

COST CliniMARK Training School
September 23rd - 27th 2019, Athens - Greece

A very successful Cost Clinimark training school was taking place from September 23 to 27, 2019 in Spetses Greece. More than 50 doctoral and post-doctoral students and academic trainers and experts discussed the "Approaches to discovery and validation of biomarkers".

Other consortia on biomarker: X-omics.nl and BIC

The Netherlands X-omics Initiative is a new facility as part of the National Roadmap for Large-Scale Research Infrastructures. It is partly funded by NWO with a total budget of 40 million euro. The project started on September 2018 and will last for ten years.

Biomarker Commercialization BIC. A consortium to assist biomarkers reach their full potential.

CliniMARK Kick-off meeting

The CliniMARK network has the goal of establishing "Best Biomarker Practice" (BBP) guidelines to radically improve the process from biomarker discovery to clinical use. The kick-off meeting was held at the COST offices in Brussels on March 14, 2017. A plan was developed to define BBP guidelines and to apply these guidelines for the validation of biomarkers with COPD as an example. The next meeting will be held from October 5 to 7, 2017, at the Erasmus MC (Rotterdam) in conjunction with the Biomarker Symposium. For further information please contact This email address is being protected from spambots. You need JavaScript enabled to view it..